1. A CD4/Foxp3/OX40 triple immunofluorescence assay determines association between T cell immune subsets and outcome in colorectal cancer. (6th November 2014) Authors: Ziai, James; Huseni, Mahrukh; Foreman, Oded; Eastham-Anderson, Jeffrey; Xiao, Yuanyuan; Chu, Felix; Kowanetz, Marcin; Hegde, Priti S; Kim, Jeong Journal: Journal for immunotherapy of cancer Issue: Volume 2(2014)Supplement 3 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. Anti-tumor efficacy and biomarker evaluation of agonistic anti-OX40 antibodies in preclinical models. (6th November 2014) Authors: Huseni, Mahrukh; Totpal, Klara; Du, Changchun; Dalpozzo, Katie; Zhu, Jing; Rishipathak, Deepali; McNamara, Erin; Jonshtone, Bernadette; Hegde, Priti S; Rhee, Ina; Damico-Beyer, Lisa; Kim, Jeong Journal: Journal for immunotherapy of cancer Issue: Volume 2(2014)Supplement 3 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. Atezolizumab as first-line treatment in cisplatin-ineligible patients with locally advanced and metastatic urothelial carcinoma: a single-arm, multicentre, phase 2 trial. Issue 10064 (7th January 2017) Authors: Balar, Arjun V; Galsky, Matthew D; Rosenberg, Jonathan E; Powles, Thomas; Petrylak, Daniel P; Bellmunt, Joaquim; Loriot, Yohann; Necchi, Andrea; Hoffman-Censits, Jean; Perez-Gracia, Jose Luis; Dawson, Nancy A; van der Heijden, Michiel S; Dreicer, Robert; Srinivas, Sandy; Retz, Margitta M; Joseph,... Journal: Lancet Issue: Volume 389:Issue 10064(2017) Page Start: 67 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
4. Atezolizumab versus chemotherapy in patients with platinum-treated locally advanced or metastatic urothelial carcinoma (IMvigor211): a multicentre, open-label, phase 3 randomised controlled trial. Issue 10122 (24th February 2018) Authors: Powles, Thomas; Durán, Ignacio; van der Heijden, Michiel S; Loriot, Yohann; Vogelzang, Nicholas J; De Giorgi, Ugo; Oudard, Stéphane; Retz, Margitta M; Castellano, Daniel; Bamias, Aristotelis; Fléchon, Aude; Gravis, Gwenaëlle; Hussain, Syed; Takano, Toshimi; Leng, Ning; Kadel, Edward E; Banchereau... Journal: Lancet Issue: Volume 391:Issue 10122(2018) Page Start: 748 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
5. Circulating and tumor-based biomarkers predict clinical activity in cancer patients treated with the engineered anti-PD-L1 antibody MPDL3280A. (6th November 2014) Authors: Kowanetz, Marcin; Rabe, Christina; Xiao, Yuanyuan; Wu, Qun J; Koeppen, Hartmut; Leddy, Cecilia; Patel, Rajesh D; Powderly, John; Kohrt, Holbrook; Gettinger, Scott; Soria, Jean-Charles; Herbst, Roy S; Desai, Rupal; Denker, Mitchell; Ruppel, Jane; Boe, Marigold; Nakamura, Rin; Fu, Ling; Sumiyoshi, ... Journal: Journal for immunotherapy of cancer Issue: Volume 2(2014)Supplement 3 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
6. Myeloid cell biology and inhibition of anti-tumor immune responses by MPDL3280A in urothelial bladder cancer. (6th November 2014) Authors: Xiao, Yuanyuan; Rabe, Christina; Kowanetz, Marcin; Powles, Thomas; Vogelzang, Nicholas J; Petrylak, Daniel P; Loriot, Yohann; Denker, Mitchell; Nakamura, Rin; Wu, Qun J; Sumiyoshi, Teiko; Boyd, Zachary; Teng, Siew-leng M; Shen, Xiaodong; Fine, Gregg; Chen, Daniel S; Hegde, Priti S Journal: Journal for immunotherapy of cancer Issue: Volume 2(2014)Supplement 3 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗